News ViiV's Cabenuva enhances control of unsuppressed HIV ViiV's long-acting injectable HIV drug, Cabenuva, has proved to be more effective than daily oral therapy for unsuppressed infections.
News Vaxcyte's pneumococcal jab exceeds expectations Shares in Vaxcyte have rocketed on phase 3 trial data for its pneumococcal vaccine VAX-31 that suggests it could take on rivals from Pfizer and MSD.
News New diabetes and obesity studies making waves at EASD As the EASD congress draws to a close, here's a round-up of some of the other clinical trials in diabetes and obesity that drew our attention.
News New Lilly combo tops tirzepatide for weight loss in diabetes Eli Lilly's bid to dominate the next generation of weight-loss therapies has been strengthened by data on its new combination therapy EloraTZP.
News Apogee buy delivers eczema trial win for AbbVie AbbVie's long-acting IL-13 inhibitor zumilokibart, part of its $10.9bn Apogee buy, has shown efficacy in atopic dermatitis and will move into phase 3.
News uniQure falls on long-term Huntington's gene therapy data uniQure's latest data drop for its gene therapy for Huntington's disease, under review in the US and UK, has spooked investors.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.